drugset / Trial / NCT05021640
Study of DCR-AUD in Healthy Volunteers
RandomizedSequentialDouble-blindTreatment
Summary
DCR-AUD will be evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Timeline
- Start
- 2021-09-21
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCR-AUD | Oligonucleotide (other) | 80 mg | Subcutaneous |
| Subject | DCR-AUD | Oligonucleotide (other) | 240 mg | Subcutaneous |
| Subject | DCR-AUD | Oligonucleotide (other) | 480 mg | Subcutaneous |
| Subject | DCR-AUD | Oligonucleotide (other) | 960 mg | Subcutaneous |